Europe Autoimmune Disease Diagnostics Market

Market Overview

In 2021, the global autoimmune disease diagnostics market size was worth USD 4,253.29 million, and by 2030, it is expected to be worth USD 8089.97 million. During the forecast period (2022–2030), the market is expected to develop at a CAGR of 7.17%. The European market is the second largest one and is expected to be valued at USD 386.12 million by 2030 its CAGR for the period of 2022-2030 is expected to be 8.10% keeping 2021 as the base year.

Autoimmune illnesses are also characterized by the activation of self-reactive T cells, the production of autoantibodies, and inflammation. Immune cells may recognize foreign substances such as bacteria and viruses and send out fighter cells to combat them. The immune system is forced to combat itself in autoimmune illnesses.

But in certain cases, the immune system misidentifies parts of your body, such as your joints or skin, as an alien in an autoimmune disease. Autoantibodies are proteins released by the body that assault healthy cells. Some autoimmune disorders are limited to a single organ. The pancreas is harmed by type 1 diabetes. Systemic lupus erythematosus (SLE), for example, affects the entire body. These are non-communicable conditions in which the immune system loses its natural balance. This organism is in charge of causing an abnormal response in its tissue cells.

Market Dynamics

Europe Autoimmune Disease Diagnostics Market Drivers

The market is being driven by the rising prevalence of the disease, as well as increased public awareness, technical developments, and greater laboratory automation.

The frequency of the most common autoimmune immunological illnesses is increasing in European countries. Multiple sclerosis is projected to affect 83 people in every 100,000 in Europe. Furthermore, women are more likely than men to develop multiple sclerosis. In addition, rheumatoid arthritis affects two million people, and psoriasis, one of the most frequent forms of autoimmune illness, is estimated to impact about 2-3% of the population. Early detection and treatment of the aforementioned disorders can make a major difference in preventing permanent harm and impairment. Diagnostic testing for autoimmune diseases can confirm a problem, quantify illness severity, and help determine prognosis. They can also be used to track illness progression.

Rheumatoid arthritis is a chronic, progressive, and inflammatory autoimmune disease characterized by persistent synovial inflammation that leads to joint deterioration. It is linked to the HLA-DR4 and HLA-DR1 serotypes. The availability of therapeutic options such as biologics, rising awareness of rheumatoid arthritis, and the presence of payment systems in many countries are all contributing to the segment's rise. Females are more likely to develop rheumatoid arthritis (RA). In the United Kingdom, for example, ladies have a prevalence rate of 1.2% and males have a prevalence rate of 0.4%.

Increased awareness of auto-immune disorders through research, education, support, and advocacy initiatives is a major driver in increasing usage rates. The European Commission is implementing a number of efforts to raise public awareness about the risk factors for acquiring autoimmune illnesses. As symptoms arise, patients can seek medical attention and begin treatment.

A growth in autoimmune disorders and market volume has been attributed to factors such as changing lifestyles, a lack of nutritional food and exercise, heavy smoking, and inconsistent sleeping habits. Furthermore, rising autoimmune disease occurrences among the senior population, owing to an increased affinity for self-antigens or latent viruses, will fuel autoimmune disease diagnostics market growth.

Antibody profiling technologies like antigen microarray and mass spectrometry have shown a wide variety of favorable findings in terms of analytical sensitivity and repeatability. With time, these methods can be integrated into routine clinic operations. Biomarker discovery has also been aided by the advent of genomic and proteomic multiplex technologies, which has increased its presence in diagnostics and therapeutic testing.

Europe Autoimmune Disease Diagnostics Market Restraints

Detecting autoimmune illnesses takes time and requires a variety of tests, including serum testing for rheumatoid arthritis, Addison's disease, and Hashimoto's disease. Furthermore, no one laboratory test can reliably diagnose the presence of an autoimmune disease with a high degree of precision.

In its consensus guidelines, the European Society of Blood and Marrow Transplantation for Immune Monitoring and Biobanking recommends SCT for severe Autoimmune Diseases but a lot of questions remain unanswered, necessitating future research to improve our understanding of the underlying mechanisms of action and therapeutic SCT regimens.

Europe Autoimmune Disease Diagnostics Market Opportunities

The demand for RA diagnosis is predicted to rise as the incidence of autoimmune disorders rises, as well as off-label prescriptions of NSAIDs and other pain relievers. Furthermore, kit makers' increased attention on the high specificity and sensitivity of RA kits, as well as favorable regulatory criteria for quick RA diagnostic kits, are projected to drive market expansion.

The growing public awareness of autoimmune disorders provides fertile ground for the development of novel and accurate diagnostic tools. The automation of laboratories and the rising shift toward replacing traditional technologies are predicted to pave the way for a larger global autoimmune disease diagnostics market.

Recent Developments

• Roche and GenMark Diagnostics signed a definitive merger agreement in March 2021, under which Roche would entirely acquire GenMark for USD 24.05 per share in an all-cash transaction.
• The Phadia 200, introduced in January 2021 by Thermo Fisher Scientific Inc., allows for unprecedented levels of flexibility and automation in laboratory testing facilities, assisting in the detection of allergy and autoimmune diseases in Europe.